GLP-1s and gallstones: the gallbladder risk explained

Key takeaways

• The risk is real but modest. A meta-analysis of 76 trials and 103,371 people found GLP-1 drugs raised the risk of gallbladder or biliary disease by about a third (relative risk 1.37), and gallstones specifically by about 27 percent (relative risk 1.27) .
• It runs higher in weight-loss trials. In the weight-loss studies specifically, the risk of gallbladder or biliary disease was more than doubled (relative risk 2.29), which points at the weight loss as much as the drug .
• The absolute numbers stay low. On the semaglutide (Wegovy) label, gallstones were reported by 1.6 percent of people versus 0.7 percent on placebo, and gallbladder inflammation by 0.6 percent versus 0.2 percent .
• Two causes, same direction. Fast weight loss makes the liver dump extra cholesterol into bile and leaves the gallbladder emptying less completely, which is why rapid weight loss of any kind forms stones . The drug class adds its own signal on top, and both the semaglutide and tirzepatide labels carry a gallbladder-disease warning .
• Know the red line. Sudden, severe pain in the upper-right belly (often after a fatty meal), pain boring through to the back or right shoulder, fever, or yellowing skin is a same-day medical call, not a wait-and-see .

Skip to:

• Why GLP-1s and fast weight loss form stones
• How big the risk actually is
• Why this is a class effect, not a one-drug problem
• What you can actually do about it
• The pain that is a same-day call
• The bottom line

Why GLP-1s and fast weight loss form stones

Gallstones on a GLP-1 have two causes pulling in the same direction, and the bigger one is often the weight loss itself, not the molecule. Gallstones form when bile holds more cholesterol than it can keep dissolved and the gallbladder does not empty briskly enough to flush it. Rapid weight loss hits both levers at once.

When you lose weight quickly, the liver releases extra cholesterol into bile, and a gallbladder that is being asked to contract less often (because you are eating less, and less fat) empties less completely. Stagnant, cholesterol-heavy bile is exactly the recipe for stones . This is not unique to GLP-1 drugs: any fast weight loss, from very-low-calorie diets to bariatric surgery, carries it, and stones or sludge have been reported in roughly 10 to 25 percent of people within the first weeks of rapid slimming .

The drug class appears to add its own contribution on top of the weight loss, which is why the gallbladder signal shows up even in trials where the weight change is modest . You do not have to untangle exactly how much is the drug and how much is the speed of loss. The practical point is that both move in the same direction, and the speed of loss is the part you and your prescriber can influence.

How big the risk actually is

The cleanest read comes from a large meta-analysis in JAMA Internal Medicine that pooled 76 randomized trials and 103,371 people. It is worth seeing the relative risks and the absolute rates side by side, because they tell different halves of the story: the relative risk says the effect is real, and the absolute rate says it is still uncommon.

The meta-analysis also found a dose-response: higher GLP-1 doses carried higher gallbladder risk (relative risk 1.56) than lower doses . That fits the weight-loss picture, since the higher doses are the ones used to drive the largest, fastest weight loss.

Why this is a class effect, not a one-drug problem

It is tempting to ask which drug is safer for your gallbladder, but that is the wrong question, and the evidence does not support a clean winner. The JAMA signal is across the GLP-1 class, not pinned to one molecule, and both of the approved weight-loss drugs carry the same warning: the semaglutide label says treatment is associated with an increased occurrence of gallstones and gallbladder inflammation, and the tirzepatide label lists acute gallbladder disease among its warnings too .

Because the weight loss is a shared driver, switching molecules to dodge gallstones is not a reliable strategy. If anything, the drug that drives faster, larger weight loss may carry more of the weight-loss-related gallbladder risk, not less. The lever that actually matters is the pace of the loss and watching for symptoms, both of which are the same regardless of which GLP-1 you are on. For the wider trade-offs between the two drugs, see tirzepatide vs semaglutide: what the trials show.

What you can actually do about it

You cannot make weight loss risk-free for your gallbladder, but you can keep the odds toward the low end and catch trouble early.

• Favor steady over crash. The gallbladder risk tracks with how fast and how far you lose, so a controlled, prescriber-led pace beats chasing the biggest number on the scale .
• Do not skip meals to nothing. Long gaps without eating, and very low-fat eating, mean the gallbladder rarely contracts, which lets bile sit and concentrate. Regular meals keep it emptying .
• Know your history. If you have had gallstones before, a strong family history, or risk factors your clinician flags, that is worth raising before and during treatment, because some prevention strategies are a prescriber decision, not a supplement-aisle one.
• Treat new upper-belly pain as information, not background noise. Most of it is not your gallbladder, but the pattern below is the one that earns a prompt call.

None of this is a reason to avoid a GLP-1 if it is right for you. The gallbladder risk is one item on a risk-and-benefit ledger that, for many people, still tilts toward treatment. It is a reason to lose weight at a sane pace and to know the warning signs, not a reason to panic.

The pain that is a same-day call

Most gallstones are silent and never cause trouble. The ones that matter announce themselves, and the pattern is specific enough to recognize.

That warning pattern is the exception. For most people on a GLP-1, the gallbladder never becomes a story, and the small added risk is the price of weight loss that is doing other good across the body.

The bottom line

GLP-1 drugs modestly raise the risk of gallstones and gallbladder disease, by about a third overall and more in weight-loss trials, but the absolute rates stay low (gallstones 1.6 percent versus 0.7 percent on placebo in the semaglutide trials) . The risk is driven as much by the rapid weight loss as by the drug, which is why it is a class effect and why the speed of loss is the lever worth pulling .

Lose weight at a controlled pace, keep eating regular meals, flag any gallstone history to your prescriber, and treat sudden severe upper-right-belly pain with fever or jaundice as a same-day call. Do that, and for most people the gallbladder stays a footnote rather than a chapter.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 5 entries, all primary canon (a JAMA Internal Medicine meta-analysis of 76 trials, the FDA prescribing information for semaglutide and tirzepatide, the NIDDK patient guidance on dieting and gallstones, and a peer-reviewed review of gallstone formation), last reviewed 2026-06-28.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Injection-site rotation overview - Public overview of the Pro site-rotation planner.